Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.50 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.48 |
| ▸ | ITGAV | P06756 | 1/20 | 0.48 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24326690 | 1.00 | TRPM8 (0.59) | TRPM8MAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL1889629 | 1.00 | TRPM8 (0.59) | TRPM8MAPTL3MBTL1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5808835 | 0.97 | TRPM8 (0.56) | TRPM8MAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL30220325 | 0.89 | TRPM8 (0.58) | TRPM8MAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL19520951 | 0.89 | TRPM8 (0.58) | TRPM8MAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL16851474 | 0.89 | TRPM8 (0.58) | TRPM8MAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL19520949 | 0.89 | TRPM8 (0.58) | TRPM8MAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL7424210 | 0.89 | TRPM8 (0.58) | TRPM8MAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL7424214 | 0.89 | TRPM8 (0.58) | TRPM8MAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL4166663 | 0.86 | TRPM8 (0.55) | TRPM8MAPTL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085060-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LTD (GB) | 2026-03-26 | — | — | US | disclosed |
| US-12441709-B2 | Therapeutic compounds | INDIVIOR UK LIMITED (GB) | 2025-10-14 | — | — | US | disclosed |
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | C4X DISCOVERY LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | C4X DISCOVERY LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | C4X DISCOVERY LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| US-20240076282-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2024-03-07 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-11753398-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| CN-116670143-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-10611760-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | C4X DISCOVERY LIMITED (GB) | 2020-04-07 | — | — | US | disclosed |
| US-20170291897-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | INDIVIOR INC. | 2017-10-12 | — | — | US | disclosed |
| US-20170291897-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | INDIVIOR INC. | 2017-10-12 | — | — | US | disclosed |
| US-20170291897-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | INDIVIOR INC. | 2017-10-12 | — | — | US | disclosed |
| EP-3189043-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | C4x Discovery Limited (GB) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034882-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | C4X DISCOVERY LIMITED (GB) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016034882-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | C4X DISCOVERY LIMITED (GB) | 2016-03-10 | — | — | WO | disclosed |
| US-20110105567-A1 | Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity | ALLERGAN, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| EP-2185506-A1 | PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY | Allergan, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009026407-A1 | PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753398-B2 | Therapeutic compounds | HCRTR2, HCRTR1, NPY1R | TRPM8 276/4885MAPT 499/4885L3MBTL1 4727/4885 |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | TRPM8 61/4885MAPT 4857/4885L3MBTL1 3940/4885 |
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | HCRTR1, HCRTR2, NPY1R | TRPM8 411/4885MAPT 557/4885L3MBTL1 4730/4885 |
| US-20240076282-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | TRPM8 276/4885MAPT 499/4885L3MBTL1 4727/4885 |
| US-20110105567-A1 | Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity | S1PR1, S1PR2, S1PR3 | TRPM8 133/4885MAPT 3241/4885L3MBTL1 4571/4885 |
| US-12441709-B2 | Therapeutic compounds | HCRTR2, HCRTR1, NPY1R | TRPM8 276/4885MAPT 499/4885L3MBTL1 4727/4885 |
| US-10611760-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | HCRTR1, HCRTR2, NPY1R | TRPM8 411/4885MAPT 557/4885L3MBTL1 4730/4885 |
| US-20170291897-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | HCRTR1, HCRTR2, NPY1R | TRPM8 411/4885MAPT 557/4885L3MBTL1 4730/4885 |
| US-20260085060-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | TRPM8 553/4885MAPT 680/4885L3MBTL1 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.